JP2021091728A5 - - Google Patents

Download PDF

Info

Publication number
JP2021091728A5
JP2021091728A5 JP2021036502A JP2021036502A JP2021091728A5 JP 2021091728 A5 JP2021091728 A5 JP 2021091728A5 JP 2021036502 A JP2021036502 A JP 2021036502A JP 2021036502 A JP2021036502 A JP 2021036502A JP 2021091728 A5 JP2021091728 A5 JP 2021091728A5
Authority
JP
Japan
Prior art keywords
ala
group
peptides
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021036502A
Other languages
English (en)
Japanese (ja)
Other versions
JP7184946B2 (ja
JP2021091728A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2021091728A publication Critical patent/JP2021091728A/ja
Publication of JP2021091728A5 publication Critical patent/JP2021091728A5/ja
Priority to JP2022187561A priority Critical patent/JP2023010979A/ja
Application granted granted Critical
Publication of JP7184946B2 publication Critical patent/JP7184946B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021036502A 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 Active JP7184946B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022187561A JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462055982P 2014-09-26 2014-09-26
US62/055,982 2014-09-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017516948A Division JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022187561A Division JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Publications (3)

Publication Number Publication Date
JP2021091728A JP2021091728A (ja) 2021-06-17
JP2021091728A5 true JP2021091728A5 (enExample) 2021-09-30
JP7184946B2 JP7184946B2 (ja) 2022-12-06

Family

ID=55582262

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2021036502A Active JP7184946B2 (ja) 2014-09-26 2021-03-08 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017516948A Active JP6851965B2 (ja) 2014-09-26 2015-09-25 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022187561A Pending JP2023010979A (ja) 2014-09-26 2022-11-24 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤

Country Status (7)

Country Link
US (5) US10030048B2 (enExample)
EP (1) EP3197474B1 (enExample)
JP (3) JP6851965B2 (enExample)
CN (2) CN106999535B (enExample)
AU (2) AU2015320341B2 (enExample)
CA (1) CA2999711A1 (enExample)
WO (1) WO2016049580A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
US20220133837A1 (en) * 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000916A2 (en) * 1989-07-06 1991-01-24 The Regents Of The University Of California Receptors for fibroblast growth factors
US5674848A (en) 1989-08-14 1997-10-07 The Regents Of The University Of California Bioreactor compositions with enhanced cell binding
US20030077825A1 (en) 1994-07-22 2003-04-24 Bhatnagar Rajendra S. Structures useful for bone engineering and methods
US5354736A (en) 1989-08-14 1994-10-11 Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
US5635482A (en) 1989-08-14 1997-06-03 The Regents Of The University Of California Synthetic compounds and compositions with enhanced cell binding
EP0487617B1 (en) 1989-08-14 1996-10-02 The Regents Of The University Of California Synthetic peptides that enhance cell binding
WO1995016709A2 (en) * 1993-12-13 1995-06-22 Biogen, Inc. Anti-mullerian hormone receptor polypeptides and antibodies thereto
US6638912B2 (en) 1995-05-01 2003-10-28 The Regents Of The University Of California Peptide compositions mimicking TGF-β activity
US5780436A (en) 1995-05-01 1998-07-14 The Regents Of The University Of California Peptide compositions with growth factor-like activity
US5661127A (en) * 1995-05-01 1997-08-26 The Regents Of The University Of California Peptide compositions with growth factor-like activity
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
US6197586B1 (en) 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
DE19951360A1 (de) * 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
WO2001082773A2 (en) 2000-04-28 2001-11-08 The Regents Of The University Of California Structures useful for bone engineering and methods
US6509318B1 (en) * 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
AUPR279101A0 (en) * 2001-01-30 2001-02-22 Cytopia Pty Ltd Protein kinase signalling
JP4943848B2 (ja) * 2003-10-07 2012-05-30 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｎｉｋに対する抗体、その調製および使用
US20060211075A1 (en) * 2005-03-02 2006-09-21 The Albert Einstein College Of Medicine Of Yeshiva University Enzyme sensors including environmentally sensitive or fluorescent labels and uses thereof
US20070009568A1 (en) 2005-06-03 2007-01-11 Bhatnagar Rajendra S Methods for immobilizing molecules on surfaces
US20060293227A1 (en) 2005-06-24 2006-12-28 Bhatnagar Rajendra S Cosmetic compositions and methods using transforming growth factor-beta mimics
US20060293228A1 (en) * 2005-06-24 2006-12-28 Bhatnagar Rajendra S Therapeutic compositions and methods using transforming growth factor-beta mimics
EP2150273A4 (en) 2007-04-27 2010-11-17 Univ Toledo MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR MOLECULE AND METHODS OF USE
WO2009013753A1 (en) * 2007-07-24 2009-01-29 Thrombotech Ltd. Peptides derived from plasminogen activator inhibitor-1 and uses thereof
CA2695374A1 (en) * 2007-08-15 2009-02-19 Amunix, Inc. Compositions and methods for modifying properties of biologically active polypeptides
EP2124060A1 (en) * 2008-05-23 2009-11-25 ETH Zurich Method for high throughput peptide/protein assay generation and assays generated therewith
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
WO2010051064A1 (en) * 2008-10-30 2010-05-06 The Trustees Of Columbia University In The City Of New York COMPOUNDS THAT INHIBIT NFκB ACTIVITY
US8614186B2 (en) * 2009-05-27 2013-12-24 Dana-Farber Cancer Institute, Inc. Inhibition of inflammation using antagonists of MUC1
CA2785038A1 (en) * 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
JP2013176368A (ja) * 2012-02-28 2013-09-09 Oncotherapy Science Ltd Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン
CN103223175B (zh) * 2013-05-23 2015-07-22 中国人民解放军第三军医大学第三附属医院 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用
US20160000682A1 (en) 2014-07-02 2016-01-07 Geoffrey Brooks Consultants Llc Peptide-Based Compositions and Methods of Use
EP3197474B1 (en) 2014-09-26 2023-06-07 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
US9943566B2 (en) 2016-03-16 2018-04-17 Geoffrey Brooks Consultants, Llc NF-κB inhibitor composition for skin health
DE202018003082U1 (de) 2018-07-03 2019-10-07 Ergon International Gmbh Fahrradsattel
US20220133837A1 (en) 2020-08-28 2022-05-05 Rajendra Sahai Bhatnagar Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases

Similar Documents

Publication Publication Date Title
US9732136B2 (en) VIP fragments and methods of use
US5470828A (en) Peptide analogs of insulin-like growth factor II
US5480869A (en) Anti-inflammatory peptide analogs and treatment to inhibit vascular leakage in injured tissues
AU7860691A (en) Method for increasing blood-brain barrier permeability
JP2023010979A5 (enExample)
WO2022002186A1 (zh) 用于修复黏膜损伤或皮肤创伤的多肽及其应用
US5386011A (en) Hexapeptide anaphylatoxin-receptor ligands
WO1990009162A2 (en) Anaphylatoxin-receptor ligands
US5387671A (en) Hexa- and heptapeptide anaphylatoxin-receptor ligands
DE69430295T2 (de) Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe
PT94702B (pt) Processo de preparacao de peptidos hemorreguladores
Deunas et al. Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme
EP3288967B1 (en) Pharmaceutical compound
JP2018500274A5 (enExample)
JP2021531246A5 (enExample)
JP2020525478A (ja) 医薬的特性が改善されたプロドラッグペプチド
US10508142B2 (en) Pharmaceutical compound
KR930012034A (ko) 급성 췌장염 치료용 브래디키닌-길항제
RU2008125167A (ru) Терапевтическое средство для ускоренного заживления кожи, содержащее в качестве активного ингредиента дезацил-грелин и его производные
ROBELECO et al. Use of interferon-a in laryngeal papillomatosis: eight years of the Cuban national programme
JPS62190198A (ja) ペプチド誘導体
TH13940A (th) เบรดีไคนิน-แอนตาโกนิส สำหรับใช้บำบัดตับอ่อน?อักเสบเฉียบพลัน
JPH0219396A (ja) 新規ペプチドおよびそれを含有する脳機能改善剤
RU98120929A (ru) Соединения со свойствами высвобождения гормона роста